多聚组氨酸融合标签在蛋白药物开发中的应用

纯化技术是制约蛋白质药物开发及其产业化的关键技术之一。构建多聚组氨酸标签融合蛋白,采用固定金属离子亲和层析进行纯化,是一种高效的蛋白质纯化策略。介绍多聚组氨酸融合标签在蛋白质药物开发中的应用基础和应用概况,分析多聚组氨酸标签在融合蛋白中的位置对亲和层析纯化的影响,总结常用的多聚组氨酸融合表达方式,并对其融合表达样品的预处理、亲和层析纯化条件及其对目的蛋白药物药用安全性和有效性的影响进行探讨。     

胸腺肽α1-Spl DnaX内含肽融合蛋白的切割动力学研究

目的:研究胸腺肽α1(Tα1)与Spl DnaX内含肽融合蛋白AS的体外切割动力学。方法:构建Tα1和SplDnaX内含肽的融合表达载体pET-AS,转化大肠杆菌BL21(DE3),经乳糖诱导获得可溶性表达的融合蛋白AS,用镍亲和层析纯化该蛋白;综合评价温度、β-巯基乙醇(β-ME)浓度和诱导切割时间对Spl DnaX内含肽介导融合蛋白AS自切割释放Tα1的影响。结果:在大肠杆菌中诱导表达了融合蛋白AS,经镍柱纯化获得该蛋白;随着温度升高和β-ME浓度增加,诱导切割时间延长,Spl DnaX内含肽介导的切割率逐渐增大;最终采用300 mmol/Lβ-ME切割24 h,融合蛋白的硫解切割率大于90%。结论:通过对Spl DnaX内含肽的诱导切割条件进行摸索,确定了最适宜的切割条件,为利用该方法制备Tα1和其他小分子多肽提供了技术基础。     

利用ELP自断裂标签在大肠杆菌中生产抗菌肽Oxysterlin 1

抗菌肽是目前最有希望的抗生素替代品,但是使用重组技术生产抗菌肽的策略大多步骤烦琐且价格昂贵,不利于抗菌肽的规模化生产.Oxysterlin 1是一种新型的天蚕素抗菌肽,主要对革兰氏阴性菌有抗菌活性,具有较低的细胞毒性.文中利用一种简单经济的方法在大肠杆菌中实现Oxysterlin 1的表达和纯化.将Oxysterlin...     

融合标签技术及其应用

融合标签最初是作为一种有效的工具用于纯化重组蛋白质,近几年的研究表明,融合标签的作用并不局限于此。本文综述了融合标签技术的发展及在生命科学研究中的各种应用,包括重组蛋白质的纯化;目的蛋白质的检测、定向固定;体内生物事件的可视化;提高重组蛋白质的产量;增强重组蛋白质的可溶性及稳定性。     

抗HIV融合多肽CP32M的制备工艺研究

目的:研究抗HIV融合多肽CP32M的制备工艺,为其临床前试验奠定基础。方法:采用固-液相混合策略规模合成目标肽,用离子交换色谱、反相高效液相色谱对粗肽进行纯化。结果:获得了利于提高合成及片段缩合效率的3条优选片段,CP32M粗品经DEAE离子交换色谱及C18反相纯化后纯度高于98%。结论:CP32M按3条片段(Ac-1-9-OH、Fmoc-10-21-OH、H-22-32-NH2)划分,可显著提高片段合成及缩合效率,DEAE阴离子交换色谱能除去大部分杂质,提高了第二步C18反相色谱纯化效率。     

恶性疟原虫杂合多肽抗原融合基因的克隆和表达

合成了５对寡核苷酸片段，分别连接在两种恶性疟原虫杂合多肽（４５肽和５８肽）抗原基因片段（ＨＰＦＧＡ和ＨＰＦＧＢ）的头部和尾部，将这两种片段分别与霍乱毒素Ｂ亚单位（ＣＴ－Ｂ）基因末端融合。两种杂合多肽抗原分别含有数个红内期和红外期有代表性的、并能被Ｔ或Ｂ淋巴细胞识别的保护性抗原表位，ＣＴ－Ｂ基因前端具有促使分泌的信号肽序列，将这两种融合基因的不同重组质粒分别转化大肠杆菌，对转化菌的培养上清检测表明融     

连接肽对融合蛋白ELP[I]_(30)-linker-eGFP相变的影响

研究G4S和Poly N连接肽对融合蛋白ELP[I]30-linker-eGFP相变的影响.将编码两种不同连接肽G4S和Poly N的绿色荧光蛋白(enhanced green fluorescent protein,eGFP)基因克隆到pET28-ELP[I]30表达载体中,在宿主菌E.coli BLR(DE3)中经IPTG诱导表达ELP[I]30-linker-eGFP,通过可逆相变循环(inverse transition cycling,ITC)及镍柱亲和层析纯化ELP[I]30-linker-eGFP蛋白.结果显示,成功构建、表达具有活性的两种连接肽的融合蛋白ELP[I]30-linker-eGFP,连接肽G4S使融合蛋白产生不可逆相变,而Poly N不影响融合蛋白可逆相变,该研究对类弹性蛋白标签的应用具有指导意义.     

重组环状胸腺五肽结构类似物Cyclo-（Cys- Arg-Lys –Asp-Val-Tyr）的制备、鉴定和活性检测

为了实现蛋白内含肽(Intein)介导的重组环状胸腺五肽结构类似物［cyclo-（Cys -Arg-Lys –Asp-Val-Tyr）,cTP］的高效制备,设计并合成编码6个氨基酸的cTP基因,克隆到表达载体pTWIN1,重组表达质粒pTW-cTp转化E.coli ER2566构建工程菌,IPTG诱导由几丁质结合域纯化标签（chitin binding domain,CBD）、2个蛋白内含肽和目的多肽组成的“多元”融合蛋白(CBD-intein1-cTP-intein2-CBD)的高效表达.几丁质柱亲合层析纯化融合蛋白后,改变pH值和温度诱导intein1 C端切割,硫醇MESNA诱导intein2 N端切割,释放N端为Cys,C端为硫酯的重组cTP线性前体,通过非保护多肽硫酯环合法实现环肽生成.激光飞行质谱结果显示,纯化产物的分子量为764.4,与环肽的理论值相符.免疫活性检测结果显示,环肽cTP较线性多肽TP-5具有更显著的促进巨噬细胞吞噬能力的活性（P<0.01）和促进B细胞抗体生成的活性（P<0.01）.     

抗肿瘤小分子多肽的研究进展

抗肿瘤小分子多肽具有分子量小、低毒性、高活性、易于穿透肿瘤细胞等特点,一些抗肿瘤小分子多肽已进入临床研究,成为肿瘤药物研发的新热点。本文从抗肿瘤小分子多肽的不同来源途径、结构改造及生物活性等方面,对其近年来的研究进展作简要概述。     

小分子泛素相关修饰物SUMO及其融合表达

小分子泛素相关修饰物(small ubiquitin-related modifier,SUMO)是一类具有高度保守序列的低分子量蛋白.在蛋白质的融合表达中,SUMO作为融合标签得到了广泛应用.与其他传统融合标签如谷胱甘肽-S-转移酶、二硫键形成蛋白A、硫氧还蛋白等相比,SUMO具有防止蛋白降解、促进蛋白折叠、能被SUMO蛋白酶专一性识别切割并在目的蛋白上不会留下氨基酸残基等优点.本文综述SUMO融合蛋白及其配套的SUMO蛋白酶在融合表达中的优势和应用.     

利用ELP-Intein系统在大肠杆菌中生产抗菌肽DLP4

DLP4 （defensin-like peptide 4）是一种新型昆虫防御素抗菌肽,对革兰氏阳性细菌具有强大的抗菌活性而且不易产生抗药性。本研究利用类弹性蛋白（elastin-like polypeptide, ELP）的相变特性和蛋白质内含子（intein, I）的C端断裂系统,通过构建重组表达质粒pET-ELP-I-DLP4,以大肠杆菌（Escherichia coli）作为宿主细胞,诱导表达后的重组蛋白通过简单的离心、pH和温度转变进行纯化得到DLP4。研究中发现,在表达纯化过程中蛋白质内含子发生了C端提前断裂。为了解决这一问题,将其断裂为N端片段（I0_N）和C端片段（I0_C）后,分别与ELP或DLP4融合,构建了pET-ELP-I0_N和pET-ELP-I0_C-DLP4两种重组表达质粒。分别在大肠杆菌中诱导表达,将表达后的菌液混合,使蛋白质内含子恢复C端断裂活性,最终得到的DLP4的得率约为1.49 mg/L。抑菌试验证明纯化的DLP4表现出预期活性,这为DLP4在原核系统中的表达纯化提供...     

High yield expression and purification of recombinant human apolipoprotein A-II in Escherichia coli

Recombinant expression systems have become powerful tools for understanding the structure and function of proteins, including the apolipoproteins that comprise human HDL. However, human apolipoprotein (apo)A-II has proven difficult to produce by recombinant techniques, likely contributing to our lack of knowledge about its structure, specific biological function, and role in cardiovascular disease. Here we present a novel Escherichia coli-based recombinant expression system that produces highly pure mature human apoA-II at substantial yields. A Mxe GyrA intein containing a chitin binding domain was fused at the C terminus of apoA-II. A 6× histidine-tag was also added at the fusion protein's C terminus. After rapid purification on a chitin column, intein auto-cleavage was induced under reducing conditions, releasing a peptide with only one extra N-terminal Met compared with the sequence of human mature apoA-II. A pass through a nickel chelating column removed any histidine-tagged residual fusion protein, leaving highly pure apoA-II. A variety of electrophoretic, mass spectrometric, and spectrophotometric analyses demonstrated that the recombinant form is comparable in structure to human plasma apoA-II. Similarly, recombinant apoA-II is comparable to the plasma form in its ability to bind and reorganize lipid and promote cholesterol efflux from macrophages via the ATP binding cassette transporter A1. This system is ideal for producing large quantities of recombinant wild-type or mutant apoA-II for structural or functional studies.     

Engineering subtilisin BPN' for site-specific proteolysis

A combination of protein engineering and substrate optimization was used to create variants of the serine protease, subtilisin BPN', which efficiently and specifically cleave a designed target sequence in a fusion protein. The broad substrate specificity of wild-type subtilisin BPN' is greatly restricted by substitution of the catalytic histidine-containing of the catalytic histidine 64 with alanine (H64A) so that certain histidine-containing substrates are preferentially hydrolysed (Carter, P., Wells, J.A. Science 237:394-399, 1987). The catalytic efficiency, (kcat/Km), of this H64A variant was increased almost 20-fold by judicious choice of substrate and by installing three additional mutations which increase the activity of wild-type subtilisin. The most favorable substrate sequence identified was introduced as a linker in a fusion protein between a synthetic IgG binding domain of Staphylococcus aureus protein A and Escherichia coli alkaline phosphatase. The fusion protein (affinity purified on an IgG column) was cleaved by the prototype H64A enzyme and its improved variant, efficiently and exclusively at the target site, to liberate an alkaline phosphatase product of the expected size and N-terminal sequence. Several features of H64A variants of subtilisin make them attractive for site-specific proteolysis of fusion proteins: they have exquisite substrate specificity on the N-terminal side of the cleavage site and yet are broadly specific on the C-terminal side; they can be produced in large quantities and remain highly active even in the presence of detergents, reductants (modest concentrations), protease inhibitors, at high temperatures, or when specifically immobilized on a solid support.     

Three-phase affinity partitioning of proteins.

Three-phase partitioning is an elegant way to separate proteins directly from even the large volumes of crude suspensions. It was found that interfacing it with a metal-affinity-based step makes the technique highly selective. As "proof of the concept," soybean trypsin inhibitor was purified 13-fold with 72% recovery. As recombinant proteins (via their polyhistidine tags) and many other naturally occurring proteins are often purified by immobilized metal ion affinity chromatography, the technique described here should prove valuable in purifying biotechnologically important proteins at a large scale.     

Ssp dnaB蛋白质内含子介导的重组人脑钠素的制备

脑钠素(BNP)是临床治疗代偿失调性心衰竭的有效药物。将脑钠素与组氨酸标签(His-tag)以及具有自我剪切功能的Ssp dnaB微型蛋白质内含子进行融合表达。表达产物经Ni-Sepharose亲和层析及体外复性处理后,用CM_纤维素对复性产物进行了浓缩,并通过改变CM-纤维素柱内的pH及温度,诱导Ssp dnaB微型蛋白质内含子的剪切作用,使脑钠素从融合蛋白中释放并与载体蛋白(His-DnaB)分离,再经C4反相高效液相色谱法进一步纯化后,从每升培养液中获得了2.8mg纯度达97%的重组人脑钠素。体外活性测定结果表明,重组人脑钠素对兔胸主动脉条具有显著的血管舒张效应,其EC50为1.94×10-6mg/mL。